This week the biotech company Denali Therapeutics announced the results of a phase 1 clinical trial of their LRRK2 inhibitor drug called ‘DNL151’. Their findings have interesting implications for the Parkinson’s community.
Can meeting the needs of women living with Parkinson’s unlock new treatments to better manage, slow, stop or even cure Parkinson’s? Re-watch our recent webinar.
Recent studies exploring iron levels in the brains of people with Parkinson’s have shown important implications for its use as a biomarker, as well as a way of potentially assessing the progression of the condition.
Would you be interested in joining the ACT PD project team? Funded by the Edmond J. Safra foundation, this 3-year programme will bring together national and international experts to develop a protocol and sustainable strategy for a multi-arm, multi-stage trial platform to investigate disease modifying…
One of the most frustrating aspects of the way we currently conduct clinical trials is the long delays between studies. Multi-Arm, Multi-Stage (or MAMS) clinical trials may represent a solution to this cumbersome problem.